Ophthalmic Eye Dropper Market size was USD 15.5 billion in 2024 and is estimated to reach USD 36.7 billion by the end of 2037, expanding at a CAGR of 6.9% during the forecast period, i.e., 2025-2037. In 2025, the industry size of the ophthalmic eye dropper is estimated at USD 16.5 billion.
The increasing prevalence of eye disorders such as glaucoma, allergies, conjunctivitis, and dry eye are reflecting a positive influence on ophthalmic eye dropper sales. The change in lifestyles, genetics, poor eating habits, high exposure to UV rays, and increasing stress levels are some of the factors leading to the cause of eye disorders. The most prevalent eye disorder is dry eye, the high exposure to screens is the leading cause of it.
Dry eye cases and vision loss are observed in almost all age groups, youngsters and adults with longer screen time. For instance, according to the Centers for Disease Control and Prevention, dry eye is most prevalent and accounts for 70% to 90% of cases of age-related macular degeneration (AMD). The same source also estimates that around 1.8 million American individuals over 40 years of age are affected by AMD. Additionally, the International Agency for the Prevention of Blindness (IAPB) estimates around 771 million globally are living with vision loss which can be treated, out of which 100 million people have cataracts. The most cases are observed in low- and middle-income countries, around 90% of the total global cases.
Considering these facts, key market players are investing heavily in producing advanced ophthalmic eye care solutions including eye drops. The rising cases of eye disorders are serious healthcare challenges but offer lucrative opportunities for ophthalmic eye dropper manufacturers. For instance, AbbVie Inc’s key product revenues, 12 months ended December 31, 2023 (unaudited) financial report reveals that the total net revenue from the eye care products accounted for USD 2415 million. Furthermore, the total reported change compared to 2022 is 10.6%.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.9% |
|
Base Year Market Size (2024) |
USD 15.5 billion |
|
Forecast Year Market Size (2037) |
USD 36.7 billion |
|
Regional Scope |
|
By Eye Dropper Type (Unidose Eye Dropper, Preserved Multi-dose Eye Dropper, Preservative-free Multi-dose Eye Dropper)
By the end of 2037, preserved multi-dose eye dropper segment is estimated to dominate ophthalmic eye dropper market share of around 49%. The convenience and multi-dose applications from single containers are some of the factors contributing to the sales growth of preserved multi-dose eye droppers. The growing adoption of preserved multi-dose type of eye droppers is due to their cost-effectiveness and effectiveness in patients who are under eye care for glaucoma, conjunctivitis, and seasonal allergies. The integration of advanced technologies is improving the shelf life of preserved multi-dose eye drop products, which further helps in reducing bacterial concern and product degradation issues.
By Mode (Prescription Drugs, Over-the-counter (OTC Drugs))
In ophthalmic eye dropper market, prescription drugs segment is set to capture revenue share of around 63.5% by the end of 2037. For any human being, eyes are a vital body part, and if they get infected by any kind of disorder such as dry eye, glaucoma, or cataract people primarily prefer to visit healthcare facilities such as hospitals and clinics for better care and effective results. This move by the patients augments a high demand for prescription-based eye droppers. The resistance to purchasing OTC drugs due to their unknown results and risk of side effects that can lead to complete blindness or damage are fuelling the sales of prescription-based eye droppers. Furthermore, prescribed drugs are manufactured through several technologically advanced procedures, which makes them effective and efficient in-patient care comfort, contributing to their high sales.
Our in-depth analysis of the market includes the following segments:
|
Eye Dropper Type |
|
|
Mode |
|
|
Indication |
|
|
End use |
|
North America Market Forecast
North America ophthalmic eye dropper market is expected to hold revenue share of more than 34.6% by 2037. The rising cases of eye disorders, the presence of advanced healthcare facilities, and continuous advancements in product formulation and delivery administration are augmenting the market growth in the region.
In the U.S., the high prevalence of eye disorders such as dry eyes, glaucoma, and cataracts is pushing the need for advanced ophthalmic eye care droppers. For instance, according to the Centers for Disease Control and Prevention, cataracts are a prime cause of vision loss in the U.S. and around 20.5 million individuals over 40 years of age are living with cataracts in both eyes and 6.1 million have replaced their lenses through operations. These statistics help to understand that with rise in the cases of eye disorders followed by operations is augmenting the demand for post-surgery ophthalmic eye drops, contributing to the overall market growth in the country.
In Canada, the presence of advanced healthcare facilities and research organizations such as the Association for Research in Vision and Ophthalmology and the Eye Care Foundation of Canada is contributing to the ophthalmic eye dropper market growth. These organizations play a vital role in the development of advanced ophthalmic eye care solutions including droppers.
Asia Pacific Market Statistics
The Asia Pacific market for ophthalmic eye droppers is projected to evolve at the fastest pace during the forecast period. The rising prevalence of eye disorders, increasing healthcare expenditure, and government awareness programs and reimbursement policies are contributing to the eye care solution sales including eye droppers.
In India, the government is investing more in advancing its healthcare infrastructure, such developments positively contribute to the medical and pharma sectors growth including ophthalmic eye droppers. For instance, according to the India Brand Equity Foundation, the Union budget 2024-2025 allocated USD 10.70 billion to transform its healthcare infrastructure.
China is witnessing a high prevalence of eye disorders including dry eye, which is directly fuelling the sales of ophthalmic eye droppers. As per Research Nester's analysis, around 21% to 30% of individuals above 40 years of age have dry eye disorder. As the prevalence rate rises, so does the ophthalmic eye dropper demand, generating profitable opportunities for key market players.
Key players in the ophthalmic eye dropper market are employing several organic and inorganic tactics such as technological advancements, new product launches, mergers & acquisitions, strategic partnerships & collaborations, and regional expansion to earn more. Industry giants are investing heavily in research and development activities to introduce innovative solutions. They are also collaborating with other players, research organizations, and tech firms to introduce smart ophthalmic eye droppers. Such advanced droppers are widely adopted by tech-savvy patients.
Some of the key players include:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?